Premier Biomedical Inc (BIEI)

[mr_kenny]

The last round of dilution was primarily used to pay off the typenex note. Hartman came to conclusion early fall that this business model of obtaining toxic loans was not sustainable and needed a cash cow to support their cancer research.

Hartman partnered with Laborde with favorable terms to bring to market a CBD pain patch (and other products) that could quickly generate revenue. This revenue generation would then allow for BIEI to become self sustaining so they could obtain traditional, non dilutive financing. This would also help them negotiate with potential partners for their cancer research.

IMO this has all been executed well and Hartman will continue to push this company forward.